MedTrace Logo

Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis

NCT01928212 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2014-07-18

No results posted yet for this study

Summary

Optical coherence tomography (OCT) is a non-invasive retinal imaging technology that can provide high-resolution cross-sectional images of the peripapillary retinal nerve fiber layer (RNFL) and measure its thickness. A reduction of the RNFL thickness has been detected in several neurodegenerative diseases, such as multiple sclerosis, CADASIL and Alzheimer's disease. Different studies have reported RNFL changes also in Parkinson's disease (PD),a common neurodegenerative disease characterized by motor dysfunctions, originally described by James Parkinson in 1817. PD is characterized by selective dopaminergic neuronal cells loss, which may correlate with RNFL thinning. Previous studies on this subject, however, reported contradicting results. Some investigations reported reductions of the RNFL thickness while others did not. In the present study, in order to determine whether RNFL thickness is reduced in PD patients, we performed a meta-analysis and systematically evaluated RNFL thickness measurements with OCT in a series of PD patients and in the healthy control groups.

Conditions

  • Parkinson Disease

Interventions

DEVICE

Optical coherence tomography

Sponsors & Collaborators

  • Wenzhou Medical University

    collaborator OTHER

  • Yifan Feng

    lead OTHER

Principal Investigators

  • Yifan Feng, PhD · Wenzhou Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-01-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928212 on ClinicalTrials.gov